AC176

DRUG2 trials

Sponsors

Accutar Biotechnology Inc

Conditions

Metastatic Castration Resistant Prostate Cancer

Phase 1

A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

TerminatedNCT05241613

Accutar Biotechnology IncMetastatic Castration Resistant Prostate Cancer

Start: 2022-03-16End: 2024-03-05Updated: 2025-02-13

A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

TerminatedNCT05673109

Accutar Biotechnology IncMetastatic Castration Resistant Prostate Cancer

Start: 2023-02-22End: 2023-10-08Updated: 2024-01-25